-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, April 25, April 23, NMPA official website showed that Guangdong Jincheng Jinsu Pharmaceutical's ceftazidime for injection passed the consistency evaluation.
Ceftazidime for injection is the fifth batch of varieties to be collected.
According to data from Minai.
com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.
Ceftazidime for injection is the fifth batch of varieties to be collected.
According to data from Minai.
com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.
Ceftazidime belongs to the third-generation semi-synthetic cephalosporins.
It has the characteristics of broad antibacterial spectrum and enzyme resistance.
It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine.
Road infection and so on.
Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.
It has the characteristics of broad antibacterial spectrum and enzyme resistance.
It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine.
Road infection and so on.
Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.
According to Meinenet data, in 2019, the sales of ceftazidime for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 6 billion yuan, and its sales in 2020H1 were close to 2.
5 billion yuan.
, Hainan Hailing Chemical Pharmaceuticals occupies more than 50% of the market share.
5 billion yuan.
, Hainan Hailing Chemical Pharmaceuticals occupies more than 50% of the market share.
Terminal Ceftazidime Sales in Public Medical Institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Ceftazidime for injection is the fifth batch of varieties to be collected.
Meters within the network database consistency evaluation, the current evaluation ceftazidime for injection through enterprises has seven, including Qilu Pharmaceutical, Pharmaceutical special times, Yangtze River Pharmaceutical, Korea and the US Pharmaceutical, Hailing Pharmaceutical, Kim So-and Hainan Jincheng Swiss co Pharmaceutical.
Meters within the network database consistency evaluation, the current evaluation ceftazidime for injection through enterprises has seven, including Qilu Pharmaceutical, Pharmaceutical special times, Yangtze River Pharmaceutical, Korea and the US Pharmaceutical, Hailing Pharmaceutical, Kim So-and Hainan Jincheng Swiss co Pharmaceutical.
Up to now, Jincheng Jinsu has passed the consistency evaluation of 3 injections, including Cefazolin Sodium for Injection, Ceftriaxone Sodium for Injection and Ceftazidime for Injection, all of which are the fifth batch of varieties to be collected.
Source: Mi Neiwang database, NMPA
Medical Network News, April 25, April 23, NMPA official website showed that Guangdong Jincheng Jinsu Pharmaceutical's ceftazidime for injection passed the consistency evaluation.
Ceftazidime for injection is the fifth batch of varieties to be collected.
According to data from Minai.
com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.
Ceftazidime for injection is the fifth batch of varieties to be collected.
According to data from Minai.
com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.
Ceftazidime belongs to the third-generation semi-synthetic cephalosporins.
It has the characteristics of broad antibacterial spectrum and enzyme resistance.
It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine.
Road infection and so on.
Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.
It has the characteristics of broad antibacterial spectrum and enzyme resistance.
It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine.
Road infection and so on.
Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.
According to Meinenet data, in 2019, the sales of ceftazidime for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 6 billion yuan, and its sales in 2020H1 were close to 2.
5 billion yuan.
, Hainan Hailing Chemical Pharmaceuticals occupies more than 50% of the market share.
5 billion yuan.
, Hainan Hailing Chemical Pharmaceuticals occupies more than 50% of the market share.
Terminal Ceftazidime Sales in Public Medical Institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Ceftazidime for injection is the fifth batch of varieties to be collected.
Meters within the network database consistency evaluation, the current evaluation ceftazidime for injection through enterprises has seven, including Qilu Pharmaceutical, Pharmaceutical special times, Yangtze River Pharmaceutical, Korea and the US Pharmaceutical, Hailing Pharmaceutical, Kim So-and Hainan Jincheng Swiss co Pharmaceutical.
Meters within the network database consistency evaluation, the current evaluation ceftazidime for injection through enterprises has seven, including Qilu Pharmaceutical, Pharmaceutical special times, Yangtze River Pharmaceutical, Korea and the US Pharmaceutical, Hailing Pharmaceutical, Kim So-and Hainan Jincheng Swiss co Pharmaceutical.
Up to now, Jincheng Jinsu has passed the consistency evaluation of 3 injections, including Cefazolin Sodium for Injection, Ceftriaxone Sodium for Injection and Ceftazidime for Injection, all of which are the fifth batch of varieties to be collected.
Source: Mi Neiwang database, NMPA
Medical Network News, April 25, April 23, NMPA official website showed that Guangdong Jincheng Jinsu Pharmaceutical's ceftazidime for injection passed the consistency evaluation.
Ceftazidime for injection is the fifth batch of varieties to be collected.
According to data from Minai.
com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.
Ceftazidime for injection is the fifth batch of varieties to be collected.
According to data from Minai.
com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.
Ceftazidime belongs to the third-generation semi-synthetic cephalosporins.
It has the characteristics of broad antibacterial spectrum and enzyme resistance.
It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine.
Road infection and so on.
Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.
It has the characteristics of broad antibacterial spectrum and enzyme resistance.
It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine.
Road infection and so on.
Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.
According to Meinenet data, in 2019, the sales of ceftazidime for terminal injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 6 billion yuan, and its sales in 2020H1 were close to 2.
5 billion yuan.
, Hainan Hailing Chemical Pharmaceuticals occupies more than 50% of the market share.
Hospital hospital hospital5 billion yuan.
, Hainan Hailing Chemical Pharmaceuticals occupies more than 50% of the market share.
Terminal Ceftazidime Sales in Public Medical Institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Ceftazidime for injection is the fifth batch of varieties to be collected.
Meters within the network database consistency evaluation, the current evaluation ceftazidime for injection through enterprises has seven, including Qilu Pharmaceutical, Pharmaceutical special times, Yangtze River Pharmaceutical, Korea and the US Pharmaceutical, Hailing Pharmaceutical, Kim So-and Hainan Jincheng Swiss co Pharmaceutical.
Enterprise business enterpriseMeters within the network database consistency evaluation, the current evaluation ceftazidime for injection through enterprises has seven, including Qilu Pharmaceutical, Pharmaceutical special times, Yangtze River Pharmaceutical, Korea and the US Pharmaceutical, Hailing Pharmaceutical, Kim So-and Hainan Jincheng Swiss co Pharmaceutical.
Up to now, Jincheng Jinsu has passed the consistency evaluation of 3 injections, including Cefazolin Sodium for Injection, Ceftriaxone Sodium for Injection and Ceftazidime for Injection, all of which are the fifth batch of varieties to be collected.
Source: Mi Neiwang database, NMPA
